Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.


NDAQ:KROS - Post by User

Keros Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Dec 12, 2024 5:15pm
35 Views
Post# 36359910

Keros Therapeutics Announces Update on the Phase 2 TROPOS Tr

Keros Therapeutics Announces Update on the Phase 2 TROPOS Tr
News; $KROS Keros Therapeutics Announces Update on the Phase 2 TROPOS TrialKeros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (&#x201C;Keros&#x201D; or the &#x201C;Company&#x201D;) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...KROS - Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities